Skip to content
Evofem Biosciences, Inc.
About Us
Mission
Management
Board of Directors
Saundra Pelletier
GILLIAN GREER, CBE, Ph.D.
KIM P. KAMDAR, Ph.D.
Tony O’Brien
Lisa Rarick, MD, FACOG
Colin Rutherford
Our Product
phexxi
®
Pipeline
In Development
Posters & Publications
Investors
Investor Overview
Events & Presentations
Press Releases
Stock Information
Financial Information
SEC Filings
Analyst Coverage
Corporate Governance
Committee Composition
Board of Directors
Charters + Code of Ethics
Investor Resources
Investor Contact
Investor FAQs
Contact
Investor Contact
Media Contact
General Contact
Careers
Sexual Satisfaction With a Vaginal pH Regulator (EVO100): Results From the AMPREVENCE Clinical Trial
Post navigation
Previous:
Characterization of Women According to Their Sexual Satisfaction After Treatment With the Novel Vaginal pH Regulator (VPR™) During the AMPOWER Study
Next:
Genitourinary Side Effects With Vaginal pH Regulator: Results From AMPOWER
Back
to
Top
